Xperi (XPER) traded down -0.58 % during a 24 hours period ending at 04:33 PM Central Europe on Monday 26th. One Xperi stock can currently be bought for about USD 5.17 on popular exchanges. Current supply of Xperi stocks is 48.8 mn. Xperi has a current market capitalization of USD 252.6 mn and approximately USD 1.9 mn worth of Xperi was traded on exchanges in the last 24 hours. Since last month end, Xperi has traded -4.95 % down. Simple moving average of last 200 days is at USD 6.47. The highest price of past 52 weeks was recorded at USD 8.75 on 07/02/2026. 52 weeks low was at USD 4.91 on 10/16/2026.

Here is how related stocks have performed in the past 24 hours:

  • Sanara Medtech (SMTI) traded down -0.24 % and now trades at USD 32.78. Sanara Medtech has a market capitalisation of USD 301.4 mn.

  • Artiva Biotherapeutics (ARTV) traded down -0.81 % and now trades at USD 6.04. Artiva Biotherapeutics has a market capitalisation of USD 300.7 mn.

  • Friedman Industries (FRD) traded up 2.95 % and now trades at USD 41.83. Current market capitalisation for Friedman Industries is USD 301.7 mn. Friedman Industries has a current price to earnings ratio of 12.59.

  • Iv Acquisition (GSRF) traded flat 0 % and now trades at USD 10.27. Current market capitalisation for Iv Acquisition is USD 302 mn. Iv Acquisition has a current price to earnings ratio of 43.98.

  • Benitec Biopharma (BNTC) traded down -1.93 % and now trades at USD 8.69. Current market capitalisation for Benitec Biopharma is USD 301.7 mn. Benitec Biopharma Limited will hold its 2026 Annual General Meeting on 24 November 2026. The hybrid session will take place in Melbourne and online, with shareholders able to vote by proxy or attendance. The agenda includes a presentation of the financial report for the year ended 30 June 2026, followed by several ordinary and special resolutions. Directors will seek approval to re‑elect Ms Sue MacLeaman and to confirm the appointments of Ms Maureen Baker and Mr Carl Stubbings as directors. Shareholders will also consider adopting the 2026 Employee Incentive Omnibus Plan, ratifying the issuance of previously granted options, and approving deferred shares for Director Dr David Atkins. A special resolution will seek shareholder approval for a 10 % placement facility, expanding the company’s ability to issue equity securities without further shareholder consent. All proposals are recommended by the board and the chair intends to vote in favour of the undirected proxies.

About Xperi

Xperi Inc. is a consumer and entertainment product and intellectual property licensing company based in San Jose, United States. The company specializes in inventing, developing, and delivering technologies integrated into smart devices, media platforms, and semiconductors. Their mission is to provide innovative solutions to customers worldwide.